Gut microbial metabolite hyodeoxycholic acid targets the TLR4/MD2 complex to attenuate inflammation and protect against sepsis

Sepsis, a critical condition resulting from the systemic inflam-matory response to a severe microbial infection, represents a global public health challenge. However, effective treatment or intervention to prevent and combat sepsis is still lacking. Here, we report that hyodeoxycholic acid (HDCA) has excellent anti-inflammatory properties in sepsis. We discovered that the plasma concentration of HDCA was remarkably lower in patients with sepsis and negatively correlated with the severity of the disease. Similar changes in HDCA levels in plasma and cecal content samples were observed in a mouse model of sepsis, and these changes were associated with a reduced abundance of HDCA-producing strains. Interestingly, HDCA administration significantly decreased systemic inflammatory responses, prevented organ injury, and prolonged the survival of septic mice. We demonstrated that HDCA suppressed excessive activation of inflammatory macrophages by competitively blocking lipopolysaccharide binding to the Toll-like receptor 4 (TLR4) and myeloid differentiation factor 2 receptor complex, a unique mechanism that characterizes HDCA as an endogenous inhibitor of inflammatory signaling. Additionally, we verified these findings in TLR4 knockout mice. Our study highlights the potential value of HDCA as a therapeutic molecule for sepsis.

Automated summary

Sepsis, a global public health challenge, lacks effective treatment or intervention. This study reveals that hyodeoxycholic acid (HDCA) has excellent anti-inflammatory properties in sepsis. HDCA administration significantly decreases systemic inflammatory responses and improves the survival of septic mice. The mechanism involves the competitive blockade of lipopolysaccharide binding to TLR4 and MD-2 receptor complex by HDCA. These findings highlight the potential value of HDCA as a therapeutic molecule for sepsis.